Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured NotesPRNewsWire • 04/20/21
Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual MeetingPRNewsWire • 04/20/21
Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021PRNewsWire • 04/19/21
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic HypersomniaPRNewsWire • 04/12/21
Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric PatientsPRNewsWire • 03/30/21
Why There Could Be at Least 1 More Big Acquisition in the Cannabis Industry This YearThe Motley Fool • 03/24/21
Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley ForumPRNewsWire • 03/22/21
Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic HypersomniaPRNewsWire • 03/18/21